Study Finds Advantages of Full-disclosure Mobile Telemetry Monitoring over Patch and Holter Methods to Diagnose Patients with Bradyarrhythmia

NEW ORLEANS, March 14, 2019 /PRNewswire/ -- Medi-Lynx Cardiac Monitoring, LLC, a leading provider of cardiac monitoring solutions, today announced results from a large retrospective analysis which demonstrated that cardiac monitoring with full-disclosure mobile cardiac telemetry (PocketECG) for up to 30 days significantly increased diagnostic yield for patients with bradyarrhythmia over Patch and Holter methods. Optimizing the Duration of Monitoring with the Diagnostic Yield for Bradyarrhythmias Using a Next Generation, Full-Disclosure Mobile Cardiac Telemetry Device (Abstract# 1219-272), will be presented at the American College of Cardiology's 68^th Annual Scientific Session in New Orleans at 9:30 a.m. on March 17.

"The combination of flexible monitoring duration and continuous full-disclosure ECG data, resulted in higher diagnostic yield of bradyarrhythmia, suggesting full-disclosure MCT may provide a valuable a new approach to more accurately diagnose at-risk patients and potentially identify those requiring pacemaker implantation to prevent serious adverse events," said Marek Dziubinski, PhD, lead author, chief technology officer and inventor of PocketECG.

Bradyarrhythmia, including unusually slow heart rate (bradycardia < 40 BPM), or blocked heart beats (2nd and 3rd degree atrioventricular blocks) and pauses, carries a significant risk of sudden cardiac death. While guidelines currently recommend the use of cardiac monitoring to evaluate patients who present with an abnormally slow heart rate, this research suggests that short-term monitoring may not be sufficient to accurately diagnose some patients, who may require an implantable pacemaker to regulate their heart rhythm.

Study Results
The retrospective study analyzed 26,567 diagnostic summary reports from full-disclosure telemetry tests recorded between Jan. 1, and Dec. 31, 2017 by US-based Medi-Lynx Cardiac Monitoring. Researchers identified 3,325 cases of bradyarrhythmia using the full-disclosure PocketECG device. 

The DY of bradyarrhythmia for continuous full-disclosure MCT monitoring for up to 30 days was:

• 175% higher than 24 hours of continuous monitoring (Holter)
• 37% higher than 7 days of continuous monitoring (Holter)
• 19% higher than 11 days of  continuous monitoring (Patch)

Of the reports analyzed:

• 618 patients were diagnosed with 2^nd or 3^rd degree atrioventricular block,
• 1,223 patients diagnosed with pause > 3s,
• 1,997 patients with bradycardia < 40 BPM.

About Medi-Lynx
Medi-Lynx Cardiac Monitoring, is the US service provider and subsidiary of MEDICALgorithmics S.A., delivering best-in-class cardiac diagnostic solutions and service to enable the best possible care for patients. The Company's team of highly-trained technicians and customer care specialists work seamlessly to provide around-the-clock monitoring, reporting, training and support for cardiology practices and their patients. To learn more, visit www.medi-lynx.com.

About PocketECG:
PocketECG is one of the world's leading online cardiac monitoring technologies. A portable device, similar to a smartphone, PocketECG streams continuous, fully labeled ECG signal for up to 30 days (www.pocketecg.com), classifies every heartbeat and detects short arrhythmia episodes, including atrioventricular blocks, while providing clinicians complete access to all data, at any point during the monitoring period and allowing to substantially increase the diagnostic yield for bradyarrhythmia over the traditional MCT methods¹ (transmitting fractions not full-disclosure ECG).

1. ("Frequency of Serious Arrhythmias Detected With Ambulatory Cardiac Telemetry," The American Journal of Cardiology, May 1, 2010, pages 1313 – 1316)

SOURCE Medi-Lynx Cardiac Monitoring